IZOZF - Alexander Tokman Joins Izotropic Board Of Directors
(TheNewswire)
VANCOUVER, BC – TheNewswire - November 11,2022 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers, announcesthat Advisor Mr. Alexander Tokman has joined theCompany’s Board of Directors .
Strengthening the Board of Directors with strategic andwell-connected industry executives is pertinent to effectivelyimplementing the Company's short and long-term milestone plans,including the intention to up-list to the Nasdaq in due course.
Mr. Tokman is a growth-driven executive leader withover 22 years of global, cross-functional profit and loss leadership,specializing in creating and commercializing new technology businessesin the Healthcare, Consumer Electronics, Semiconductor and AI sectorsfor Fortune 100, technology Micro-Cap and Start-Up companies. Hisextensive experience includes leading several global business unitswithin GE Healthcare, where he led the creation, commercialization,and growth of several new global medical imaging businesses, includingPET/CT and Molecular Imaging, as well as growing more establishedmodalities such as X-Ray and Mammography. Mr. Tokman also serves as anindependent board director on a Nasdaq traded biotech company and theAmerican Academy of Thermography, a non-profit organization focused onbringing novel infrared imaging applications for diseasesdiagnosis.
As an Advisor to the Company since 2020, Mr. Tokman hascontributed by making key introductions and providing important adviceon the development, manufacturing, and marketing aspects ofoperations.
Izotropic is nearing the completion andunveiling of the first IzoView commercial prototype and subsequentclinical study for market authorization in the USA, and will continueto align with specialized executives and operational personnel on itspath to revolutionizing the breast imaging industry with Breast CTtechnology.
ON BEHALF OF THE BOARD
Dr. John McGraw
Investor Relations Contact:
James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify suchinformation and statements by using words such as"anticipate," "believe," "envision,""estimate," "expect," "intend,""may," "plan," "predict,""project," "target," "potential,""will," "would," "could,""should," "continue," "contemplate" andother similar expressions and derivations thereof in connection withany discussion of future events, trends or prospects or futureoperating or financial performance, although not all forward-lookingstatements contain these identifying words.
These statements are not guarantees of performance andinvolve risks including those related to capital requirements, anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Company nor its shareholders,officers, and consultants shall be liable for any action and theresults of any action taken by any person based on the informationcontained herein, including, without limitation the purchase or saleof Company securities. Nothing in this document should be deemed to bemedical or other advice of any kind. All images are for illustrativepurposes only. IzoView is not yet approved for sale.
Copyright (c) 2022 TheNewswire - All rights reserved.